Descripción de la empresa
Theriva Biologics, Inc. operates as a clinical-stage enterprise dedicated to the development of therapeutics designed to address cancer and related diseases in areas characterized by high unmet medical need within the United States. The company functions within the healthcare sector, specifically the biotechnology industry, positioning itself to leverage emerging technologies for oncological applications rather than established pharmaceutical manufacturing. At a fundamental scale level, Theriva Biologics, Inc. reports a market capitalization of $11.45M and employs a workforce of 15 individuals to advance its research and development pipeline. The combination of a market cap of $11.45M and reported annual revenue classified as N/A indicates that the company is an early-stage micro-cap entity where valuation is driven primarily by potential asset value and clinical trial progress rather than current operational profitability or sales volume.
Salud financiera
The financial performance metrics for Theriva Biologics, Inc. reveal significant operational losses, with reported revenue (TTM) listed as N/A and a net income (TTM) of $-25,249,000, while EBITDA stands at $-14,912,000. The substantial disparity between the reported revenue figures and the net income loss of $-25,249,000, coupled with an EBITDA of $-14,912,000, highlights a cost structure dominated by high research and development expenditures typical of clinical-stage biotechnology firms where revenue generation has not yet offset operational costs. The company reports a free cash flow of $-5,976,500, indicating a continued burn rate that consumes cash reserves to fund ongoing clinical trials and operational overhead without generating positive cash flow from operations. All three reported margins—gross margin, operating margin, and profit margin—are recorded at 0.0%, a figure that reflects the company's status as a pre-revenue entity where traditional profitability metrics are not applicable due to the absence of significant sales revenue. On the liability side, the company holds $13.06M in cash against $2.63M in debt, resulting in a debt-to-equity ratio of 17.09 which suggests a capital structure heavily reliant on equity financing rather than debt leverage. Despite the high debt-to-equity ratio, the current ratio of 1.74 indicates a conservative short-term liquidity position where current assets exceed current liabilities by a comfortable margin, providing sufficient runway to meet immediate obligations. Return on Equity is calculated at -137.8% and return on assets is -25.5%, metrics that mathematically reflect the dilution of shareholder value and asset base relative to the accumulated net losses rather than an indication of management inefficiency in a traditional operational context.
Evaluación de valoración
The valuation metrics for Theriva Biologics, Inc. present a complex picture given the lack of historical earnings, with a P/E Ratio (TTM) listed as N/A and a forward P/E of -1.25. The negative forward P/E of -1.25 implies that the market is pricing in future earnings expectations that are currently negative, preventing the use of traditional trailing multiples to assess intrinsic value. The price-to-book ratio is 0.58, indicating that the stock trades at a significant discount to its book value, which often occurs in biotech firms where assets are heavily weighted towards intangible intellectual property and research rather than physical capital. Alternative valuation metrics such as the price-to-sales ratio, which is N/A, and the EV/EBITDA of -0.07, further underscore the inability to value the company using standard public company multiples due to the lack of sales and negative earnings. Regarding trading ranges, the 52-week high is $1.50 and the 52-week low is $0.16, placing the current trading environment within a highly volatile band that spans a nearly tenfold difference between the high and low points. The beta value of 0.47 suggests that the stock exhibits lower volatility relative to the broader market, moving less than half as much as the market index, which provides a unique risk profile for a small-cap biotechnology stock that typically displays high correlation with market swings.
Growth & Income
Theriva Biologics, Inc. reports revenue growth (YoY) as N/A and earnings growth (YoY) as N/A, meaning that year-over-year expansion metrics cannot be calculated due to the absence of comparable historical revenue data in the current reporting period. Since the company is a clinical-stage entity with no revenue, the earnings growth rate is effectively non-existent, implying that growth is currently driven by clinical trial milestones and partnership announcements rather than commercial sales expansion. As a non-dividend payer with a dividend yield of N/A and a payout ratio of 0.0%, the company does not distribute cash to shareholders and instead retains all available liquidity to fund its research and development pipeline. The overall growth and income profile is defined entirely by the potential for future commercialization of its lead product candidate, VCN-01, rather than current financial performance or income generation capabilities.